[{"address1": "245 Hammersmith Road", "city": "London", "zip": "W6 8PW", "country": "United Kingdom", "phone": "44 20 8154 4600", "website": "https://www.achillestx.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Achilles Therapeutics plc, a biopharmaceutical company, develops precision T cell therapies to treat solid tumors. Its platform identifies mutations formed early in the development of cancer. The company offers PELEUS, a proprietary AI-powered bioinformatics platform, used to identify clonal neoantigens in a patient. It also develops CHIRON, which is in Phase I/IIa clinical trial for use in the treatment of advanced non-small cell lung cancer; and THETIS, a product candidate in Phase I/IIa clinical trial for use in the treatment of metastatic or recurrent melanoma. The company was formerly known as Achilles TX Limited and changed its name to Achilles Therapeutics Plc in February 2021. Achilles Therapeutics Plc was founded in 2016 and is headquartered in London, the United Kingdom.", "fullTimeEmployees": 204, "companyOfficers": [{"maxAge": 1, "name": "Dr. Iraj  Ali Ph.D.", "age": 48, "title": "CEO & Director", "yearBorn": 1975, "fiscalYear": 2023, "totalPay": 1698000, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Sergio A. Quezada Ph.D.", "age": 48, "title": "Founder & Chief Scientific Officer", "yearBorn": 1975, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Robert  Coutts", "age": 39, "title": "Chief Financial Officer", "yearBorn": 1984, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Mark William Lowdell BSc, FRCPath, MICR, MSc, Ph.D.", "age": 60, "title": "Founder & Member of Scientific Advisory Board", "yearBorn": 1963, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Charles  Swanton FMEDSCI, M.D., Ph.D.", "age": 51, "title": "Founder & Member of Scientific Advisory Board", "yearBorn": 1972, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Lee M. Stern", "title": "Vice President of Investor Relations & External Communications", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Daniel Carey Cazel Hood", "title": "General Counsel & Company Secretary", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Julia  Wilson", "title": "Head of Communications", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Tariq  Ahmed", "title": "Executive Vice President of People", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Edward  Samuel", "title": "Executive Vice President of Technical Operations", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 4, "previousClose": 1.14, "open": 1.16, "dayLow": 1.1256, "dayHigh": 1.17, "regularMarketPreviousClose": 1.14, "regularMarketOpen": 1.16, "regularMarketDayLow": 1.1256, "regularMarketDayHigh": 1.17, "beta": 1.344, "forwardPE": -9.5008335, "volume": 68175, "regularMarketVolume": 68175, "averageVolume": 163496, "averageVolume10days": 383290, "averageDailyVolume10Day": 383290, "bid": 1.13, "ask": 1.17, "bidSize": 100, "askSize": 200, "marketCap": 48700968, "fiftyTwoWeekLow": 0.63, "fiftyTwoWeekHigh": 1.76, "fiftyDayAverage": 1.0387, "twoHundredDayAverage": 0.91806, "currency": "USD", "enterpriseValue": -46683944, "floatShares": 20834031, "sharesOutstanding": 41100000, "sharesShort": 159245, "sharesShortPriorMonth": 358114, "sharesShortPreviousMonthDate": 1727654400, "dateShortInterest": 1730332800, "sharesPercentSharesOut": 0.0039, "heldPercentInsiders": 0.06515, "heldPercentInstitutions": 0.59297, "shortRatio": 1.69, "shortPercentOfFloat": 0.0063, "impliedSharesOutstanding": 42716400, "bookValue": 3.465, "priceToBook": 0.3290332, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1719705600, "netIncomeToCommon": -63967000, "trailingEps": -1.66, "forwardEps": -1.87, "enterpriseToEbitda": 0.708, "52WeekChange": 0.3411765, "SandP52WeekChange": 0.25443196, "exchange": "NCM", "quoteType": "EQUITY", "symbol": "ACHL", "underlyingSymbol": "ACHL", "shortName": "Achilles Therapeutics plc", "longName": "Achilles Therapeutics plc", "firstTradeDateEpochUtc": 1617197400, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EST", "uuid": "cd1224e6-3b8c-3fc4-8e0c-3cb68aaed9cf", "messageBoardId": "finmb_408338329", "gmtOffSetMilliseconds": -18000000, "currentPrice": 1.1401, "targetHighPrice": 0.5, "targetLowPrice": 0.5, "targetMeanPrice": 0.5, "targetMedianPrice": 0.5, "recommendationMean": 3.0, "recommendationKey": "hold", "numberOfAnalystOpinions": 1, "totalCash": 95111000, "totalCashPerShare": 2.315, "ebitda": -65899000, "totalDebt": 4463000, "quickRatio": 7.937, "currentRatio": 8.242, "debtToEquity": 3.865, "returnOnAssets": -0.26819, "returnOnEquity": -0.44219002, "freeCashflow": -30137000, "operatingCashflow": -48000000, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2025-01-02"}]